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Open AccessR E S E A R C H  A R T I C L EResearch articleArray-based gene expression, CGH and tissue data 
defines a 12q24 gain in neuroblastic tumors with 
prognostic implication
Maija Wolf*1,2, Miikka Korja3,4, Ritva Karhu5, Henrik Edgren1,2, Sami Kilpinen1, Kalle Ojala1, Spyro Mousses6, 
Anne Kallioniemi5 and Hannu Haapasalo7
Abstract
Background: Neuroblastoma has successfully served as a model system for the identification of neuroectoderm-
derived oncogenes. However, in spite of various efforts, only a few clinically useful prognostic markers have been 
found. Here, we present a framework, which integrates DNA, RNA and tissue data to identify and prioritize genetic 
events that represent clinically relevant new therapeutic targets and prognostic biomarkers for neuroblastoma.
Methods: A single-gene resolution aCGH profiling was integrated with microarray-based gene expression profiling 
data to distinguish genetic copy number alterations that were strongly associated with transcriptional changes in two 
neuroblastoma cell lines. FISH analysis using a hotspot tumor tissue microarray of 37 paraffin-embedded 
neuroblastoma samples and in silico data mining for gene expression information obtained from previously published 
studies including up to 445 healthy nervous system samples and 123 neuroblastoma samples were used to evaluate 
the clinical significance and transcriptional consequences of the detected alterations and to identify subsequently 
activated gene(s).
Results: In addition to the anticipated high-level amplification and subsequent overexpression of MYCN, MEIS1, CDK4 
and MDM2 oncogenes, the aCGH analysis revealed numerous other genetic alterations, including microamplifications 
at 2p and 12q24.11. Most interestingly, we identified and investigated the clinical relevance of a previously poorly 
characterized amplicon at 12q24.31. FISH analysis showed low-level gain of 12q24.31 in 14 of 33 (42%) neuroblastomas. 
Patients with the low-level gain had an intermediate prognosis in comparison to patients with MYCN amplification 
(poor prognosis) and to those with no MYCN amplification or 12q24.31 gain (good prognosis) (P = 0.001). Using the in 
silico data mining approach, we identified elevated expression of five genes located at the 12q24.31 amplicon in 
neuroblastoma (DIABLO, ZCCHC8, RSRC2, KNTC1 and MPHOSPH9). Among these, DIABLO showed the strongest activation 
suggesting a putative role in neuroblastoma progression.
Conclusions: The presented systematic and rapid framework, which integrates aCGH, gene expression and tissue data 
to obtain novel targets and biomarkers for cancer, identified a low-level gain of the 12q24.31 as a potential new 
biomarker for neuroblastoma progression. Furthermore, results of in silico data mining suggest a new neuroblastoma 
target gene, DIABLO, within this region, whose functional and therapeutic role remains to be elucidated in follow-up 
studies.
Background
Cancer is a complex disease caused by mechanisms that
disrupt cell homeostasis in many levels. Such mecha-
nisms include aberrations affecting gene copy numbers,
leading to altered gene expression and deregulation of
critical signalling pathways. Neuroblastoma is an early
childhood malignancy arising from undifferentiated neu-
roectodermal cells derived from the neural crest. These
neural crest precursor cells are committed to differentiate
into cells that make up sympathetic ganglia or the adrenal
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Page 2 of 13medulla. The most well known genetic alteration in neu-
roblastoma is the amplification of the MYC-related onco-
gene (MYCN) [1,2], which is still the only prognostically
significant oncogene amplification in neuroblastoma
[3,4]. Despite numerous other genetic alterations in neu-
roblastoma, such as deletions/losses/gains of 1p36, 1q,
2p13-p14, 3p21, 3p26, 3q24-p26, 4q33-q35, 6p11-p22,
11q23, 12q, 14q32, 17q and 19q [5-17], none of these
alterations has been consistently shown to have a definite
independent value in treatment stratifications. Unfortu-
nately, the main genetic alteration, MYCN amplification,
does not explain the poor outcome of all neuroblastoma
patients, suggesting that additional biomarkers of disease
progression are still needed.
Here, we present a systematic and rapid genomics data
analysis framework, which integrates DNA, RNA and tis-
sue data to identify clinically relevant biomarkers for neu-
roblastoma. In more detail, high-resolution aCGH was
utilized to identify novel genetic alterations in two neuro-
blastoma cell lines, NGP and IMR-32. Through the inte-
gration of gene copy number and gene expression data,
the impact of copy number changes on expression levels
was determined. Fluorescence in situ hybridization
(FISH) on a tissue microarray (TMA) format was used to
assess the clinical significance of the identified copy num-
ber increase at 12q24.31 in neuroblastoma patients.
Finally, we used in silico data mining of publicly available
transcriptomics data, to evaluate the transcriptional con-
sequences of the detected 12q24.31 alteration and to
identify subsequently activated gene(s).
Methods
Neuroblastoma cell cultures and sample preparation
NGP and IMR-32 neuroblastoma cells were cultured in
RPMI 1640 medium supplemented with 10% fetal bovine
serum (FBS) and 2 mM L-glutamine, and Minimum
Essential Medium supplemented with 10% FBS, 2 mM L-
glutamine, 1% non-essential amino acids and 1% sodium
pyruvate, respectively. mRNA was isolated from the sam-
ples using FastTrack 2.0 mRNA isolation kit (Invitrogen,
Carlsbad, CA). Genomic DNAs were obtained from the
same samples by swirling a glass rod in the cell lysate, fol-
lowed by standard phenol-chloroform purification.
Oligonucleotide array-based comparative genomic 
hybridization
A 95K high-resolution oligonucleotide array (Agilent
Technologies, Palo Alto, CA) was used for the detection
of copy number changes in NGP and IMR-32 cell lines.
Normal male DNA was used as a reference for both cell
lines (Cat. # G1471, Promega, Madison, WI). Sample pro-
cessing and hybridization was performed according to
the August 2005 (version 2) protocol (Agilent Technolo-
gies), with minor modifications. Briefly, 10 μg of genomic
DNA was digested overnight with AluI and RsaI (Life
Technologies, Inc., Rockville, MD). Digested DNA sam-
ples were subjected to standard phenol-chloroform puri-
fication. 4 μg of digested tumor DNA and reference DNA
were labelled with Cy5-dUTP and Cy3-dUTP (Perkin-
Elmer, Wellesley, MA), respectively, in a random priming
reaction using a BioPrime Array CGH Genomic Labelling
Module (Invitrogen, Carlsbad, CA.). After labelling,
tumor DNA and reference DNA samples were pooled,
cleaned and hybridization cocktails were prepared
according to the protocol. Hybridization and washes were
also performed according to the protocol. A laser confo-
cal scanner (Agilent Technologies) was used to obtain
signal intensities from targets and Feature Extraction
software (version 8.1.1.1, Agilent Technologies) was used
in image analysis with settings recommended by the
manufacturer (44K_CGH_0605). The CGH Analytics
software was used for analysis of aCGH data (version
3.2.32, Agilent Technologies). Control hybridizations
(male vs. male, male vs. female) were used to estimate the
baseline variation in the hybridizations, and hybridiza-
tion quality metrics provided by CGH Analytics were
evaluated to ensure good data quality.
Amplifications and losses were defined at loci with log2
copy number ratios >2 (amplification) or <0.5 (loss). Loci
with log2 copy number ratio > 3.5 were considered as
high-level amplifications.
Gene expression analyses
Gene expression levels from NGP and IMR-32 cell lines
were measured using Affymetrix GeneChip Human
Genome U133 Plus 2.0 arrays (Affymetrix, Santa Clara,
CA). In addition, a pooled sample consisting of 16 differ-
ent cancer cell lines was analyzed as a reference sample.
Sample processing and labelling were performed accord-
ing to the protocol provided by the Affymetrix. Briefly, 3
μg of mRNA was used for one-cycle cDNA synthesis
using a T7-oligo(dT) promoter primer, followed by
RNase H-mediated second-strand cDNA synthesis and in
vitro transcription reaction with biotinylated ribonucle-
otide analogs. Biotin-labelled target cRNAs were frag-
mented and the quality of labelling procedures was
assessed with GeneChip Test3 arrays. Hybridizations to
U133 Plus 2.0 arrays were performed for 16 hours at
45°C, followed by automated array washing and staining
procedures. Arrays were scanned immediately after stain-
ing using a GeneChip scanner (Affymetrix). Basic
GeneChip array analysis was performed for the obtained
image file. Data preprocessing was done using the MAS5
algorithm implemented in the Bioconductor package
"affy" [18].
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Page 3 of 13Data from both aCGH and gene expression analysis has
been deposited in NCBI's Gene Expression Omnibus
(GEO) and are accessible through Series record
GSE18144.
Integration of the aCGH and gene expression data
Expression ratios for the NGP and IMR32 cell lines were
calculated as the log2 ratio of the cell line divided by the
reference pool hybridization. A gene was considered
over- or underexpressed if its expression ratio was within
the top or bottom 7% of ratios in that sample, respec-
tively. Expression and copy number data was integrated
as follows: Affymetrix probe sets were mapped to
Ensembl gene IDs or the base pair position given by
Affymetrix, if no matching Ensembl gene id was found. A
copy number ratio for each probe set was then calculated
as the median of CGH array oligos located within 50 kb of
the probe set's genomic position. In order to investigate
the impact of copy number on expression ratios, genes
were divided into bins based on their copy number and
the frequency of over- and underexpressed genes in each
bin was calculated.
Hotspot FISH on a neuroblastoma TMA
For the TMA construction, a total of 37 archival paraffin-
embedded neuroblastomas were obtained from the
Turku University Hospital and the Tampere University
Hospital, Finland. These tumor samples represented a
vast proportion of all neuroblastomas diagnosed in these
two hospitals during 1967-2001. All the tumors were
immunohistochemically stained and microscopically re-
evaluated by two experienced pathologists. For histologi-
cal typing and grading (excluding one intracranial tumor
and two cytotoxically pretreated tumors), the INPC defi-
nition was applied [19]. The 34 classified tumors (31 pri-
mary tumors and three metastases) comprised 31
neuroblastomas (14 undifferentiated, eight poorly differ-
entiated, and nine differentiating), two ganglioneuroblas-
tomas (one nodular, one intermixed) and one
ganglioneuroma. Of these 34 cases, nine (26%) were with
favourable, and 25 (74%) with unfavourable histology.
The most proliferative areas of the tumors, i.e.
hotspots, were selected to be sampled for the TMA using
core biopsies with a diameter of 2 mm. More detailed
TMA characteristics and data on the construction of
hotspot neuroblastoma TMA have been described previ-
ously [20]. Twelve bacterial artificial chromosome (BAC)
clones from 12q13-q14 (RP11-846E20, RP11-66N19),
12q15 (RP11-1024C4, RP11-77H17), and 12q24.31
(RP11-44F24, RP11-87C12, RP11-94C5, RP11-512 M8,
RP11-152E17, RP11-679G17, RP11-1059L20, and RP11-
486O12) were labelled with digoxigenin-11-dUTP (Roche
Applied Science, Basel, Switzerland) using random prim-
ing. A spectrum Green labelled chromosome 12 specific
centromere probe (Vysis Inc. Downers Grove, IL) was
used as a reference. FISH on the neuroblastoma TMA
containing 37 samples was performed as described [21],
except that the fixation of the slides was performed using
7% formalin for 10 min. The BAC probes were detected
with anti-digoxigenin-Rhodamine (Roche Applied Sci-
ence), and nuclei counterstained with 0.1 M 4',6-diamid-
ino-2-phenylindole. The fluorescence signals were scored
from non-overlapping nuclei using Olympus BX50 epif-
luorescence microscope (Tokyo, Japan). The entire tissue
area was evaluated and 20-60 representative non-overlap-
ping nuclei were scored. A 1.5-fold increase in the test
probe copy number relative to the chromosome 12 cen-
tromere was considered as gain in copy number. MYCN
amplification status was assessed using the chromogenic
in situ hybridization technique as described [20].
Differences between groups in categorical data were
analyzed by means of the Pearson chi-square test. Overall
survival analysis was computed by means of the Kaplan-
Meier method, and the difference between the curves was
compared with the log-rank test. A Cox multivariate
regression analysis was performed to assess whether age,
stage and INPC could confound the results. All statistical
analyses were performed with SPSS 16.0.2 for Windows
and P values of < 0.05 were considered statistically signif-
icant.
In silico screening for deregulated genes at 12q24
In order to evaluate the in vivo effect of the 12q24.31 gain
in gene regulation, we performed in silico data mining of
a large collection of data from the integrated microarray
data resource GeneSapiens, studying its neuroblastoma
and healthy samples. Briefly, GeneSapiens http://
www.genesapiens.org/ is a collection of 9873 Affymetrix
microarray experiments. All data is re-annotated and
normalized with a custom algorithm so that all data in the
database are directly comparable, with extensive biologi-
cal and clinical annotation. The data is collected from
various publicly available sources such as Gene Expres-
sion Omnibus and ArrayExpress. The data consists of five
different Affymetrix microarray generations and covers
175 different cancers and tissue types. For a more in-
depth description, see [22,23].
Gene expression levels across the data, including 308-
445 healthy nervous system samples and 22-123 neuro-
blastoma samples, were examined. The exact number of
samples available for gene expression data enquiry was
dependent on the array generation that was used in the
original study. We searched for a gene expression pattern
showing higher expression in the neuroblastoma samples
compared to the healthy nervous system samples, healthy
peripheral nervous system samples, as well as healthy
samples in general, indicating gene activation specifically
in neuroblastoma. This was done using the Mann-Whit-
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mates the likelihood that the two sets of data come from
the same origin. The expression patterns of the known
oncogenes MYCN, MEIS1 and ALK were used as positive
controls. The data repository accession numbers and ref-
erences to the corresponding publications have been
indicated in Table 1.
Results
Genome-wide copy number alterations in neuroblastoma 
cell lines by array-CGH
aCGH analysis revealed several copy number changes in
both cell lines (Figure 1). The most prominent copy num-
ber alterations in the IMR-32 cell line affected the short
arm of chromosome 2, where three clearly distinct high-
level amplifications at 2p24.3, 2p14 and 2p13.3 (14.7-16.0,
66.7-67.6, 69.1-69.3 Mb from the p-telomere) were
detected, including loci for MYCN, MEIS1 (myeloid eco-
tropic viral integration site 1 homolog) and ANTRX1/
TEM8 (anthrax toxin receptor 1/tumour endothelial
marker 8), respectively. In addition, a high-level micro-
amplification at 2p23 affecting only two probes for the
ALK (anaplastic lymphoma kinase) gene was observed.
Loss of copy number was detected at e.g. 1p (0-50.7 Mb)
and 16q (68.3-88.7 Mb) in the IMR-32 cell line.
NGP cells showed high-level amplification of MYCN at
2p24.2-p24.3 (16.0-16.9 Mb from the p-telomere), as well
as several loci at 12q, including 12q14.1, 12q15, 12q24.11
and 12q24.31 (56.4-59.4, 67.2-69.3, 108.0-108.2 and
119.9-122.4 Mb from the p-telomere) (Figure 2.). Altered
regions included known targets, such as CDK4 (cyclin-
dependent kinase 4) and SAS (sarcoma amplified
sequence), as well as MDM2 (mouse double minute 2
homolog), for 12q14.1 and 12q15 amplifications, respec-
tively. The previously unidentified microamplification at
12q24.11 involved ACACB (acetyl-Coenzyme A carboxy-
lase beta) and FOXN4 (forkhead box N4) genes, whereas
several genes were included in the detected 12q24.31
amplification. Losses of copy number were observed on
chromosomes 10 (121.6-135.4 Mb), 11 (99.1-134.4 Mb)
and 19 (57.0-58.9 Mb) in the NGP cell line.
Table 1: Origin of the gene expression data used for the in silico analysis.
Sample set Data repository accession 
number *
Number of samples Reference to the 
corresponding publication
Neuroblastoma samples E-MEXP-83 10 [41]
GSE3960 22 [42]
Healthy peripheral nervous 
system samples
GSE1133 10 [43]
GSE3526 8 NA
GSE96 2 [44]
Healthy central nervous 
system samples
E-AFMX-2 27 [45]
E-TABM-20 8 [46]
GSE1133 38 [43]
GSE1297 9 [47]
GSE2164 87 [48]
GSE2361 9 [49]
GSE3526 184 NA
GSE3960 1 [42]
GSE5388 31 [50]
GSE5389 11 [50]
GSE6955 3 [51]
GSE96 17 [44]
* Data sets with accession numbers E-MEXP-83, E-AFMX-2 and E-TABM-20 have been deposited at ArrayExpress Archive http://
www.ebi.ac.uk/microarray-as/ae/, while all other data sets have been deposited at Gene Expression Omnibus http://www.ncbi.nlm.nih.gov/
geo/.
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Page 5 of 13Impact of copy number alterations on gene expression
Comparison between DNA and RNA level data showed
that gene expression levels across the genome were sig-
nificantly influenced by copy number changes (Figure 3).
The majority of the most highly amplified and overex-
pressed genes were located in the 2p and 12q amplicons.
MYCN was identified as the target for 2p24 amplification
in both cell lines. Other genes implicated in the IMR-32
cells in this region were FAM84A/NSE1 (family with
sequence similarity 84, member A) and NAG (neuroblas-
toma-amplified protein). In IMR-32, the 2p14 amplicon
showed overexpression of both MEIS1 and ETAA16, and
TEM8/ANTRX1 was overexpressed at 2p13.3.
Genes implicated in the NGP cells at 2p24 were MYC-
NOS (MYCN opposite strand) and FAM49A. At 12q, sev-
eral genes were shown to be upregulated in the distinct
amplicons in the NGP cell line. In addition to the previ-
ously reported SAS gene, amplification and overexpress-
sion of e.g. CENTG1/PIKE (centaurin, gamma 1) and
AVIL (advillin) were observed at 12q14.1. The 12q15
Figure 1 Genome-wide copy number profiles of NGP and IMR-32 neuroblastoma cell lines. Amplified and deleted regions are visualized as hor-
izontal shifts to right and left of zero line, respectively.
NGP
IMR-32
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MDM2 as well as several neighbouring genes, such as
FRS2 (fibroblast growth factor receptor substrate 2),
CPM (carboxypeptidase M) and CPSF6 (cleavage and
polyadenylation specific factor 6). The 12q24.11 micro-
amplification, which involved only ACACB and FOXN4,
caused moderately increased expression of both genes in
comparison to the reference sample. The most distal 12q
amplicon, which is located at q24.31, included RSN (res-
tin) as well as several amplified and overexpressed genes
with an unknown role in neuroblastoma. Using hotspot
FISH, the frequency and clinical significance of this pre-
viously poorly characterized 12q24.31 amplification in
neuroblastoma was explored and compared to the fre-
quency of 12q14-q15 amplification.
Copy number alterations at 12q and the clinical 
significance of the q24 gain
DNA copy number alterations at 12q14, 12q15 and
12q24.31 were analyzed using the hotspot neuroblastoma
TMA format. Altogether, 2 out of 31 (6%), 6 out of 32
(19%) and 14 out of 33 (42%) informative samples showed
copy number gain at 12q14, 12q15 and 12q24.31, respec-
tively. Although high-level copy number gains of
12q24.31 were not seen in the clinical neuroblastoma
samples (the mean ratio between test and centromeric
probes was 1.7), a survival analysis provided evidence
that low-level gain of 12q24.31 was a prognostic factor of
neuroblastoma patients (P = 0.001) (Figure 4). Patients
without MYCN or 12q24.31 amplification had the best
prognosis, patients with the gain of 12q24.31 region had
Figure 2 Copy number alterations in chromosome 12 detected in the NGP cell line. The chromosome view (left) displays the copy number pro-
file of NGP cell line versus normal male reference. The gene view (right) magnifies the selected amplification regions at 12q14.1, 12q15, 12q24.11 and 
12q24.31, indicating the log2 copy number ratios of individual oligos.
Chr. 12
-4     -2          -1           0          +1         +2    +4 -4                -2                      -1                           0                         +1                      +2     +4  
Chr 12: 53503752 - 61946877 bp
12q14 1
NGP
4 2 1 0 1 2 4
Chr 12: 63544951 - 71898076 bp
.
Incl. CDK4 & SAS
-                 -                       -                                                     +                       +      +
12q15
Incl MDM2
-4                -2                      -1                           0                         +1                      +2     +4  
Chr 12: 103925504 - 112278629 bp
.
12q24.11
ACACB, FOXN4
-4                -2                      -1                           0                         +1                      +2     +4  
Chr 12: 116973486 - 125326611 bp
12q24.31
Incl. DIABLO
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Page 7 of 13an intermediate prognosis, and patients with MYCN-
amplified neuroblastomas had the worst prognosis (Fig-
ure 4). Interestingly, 12q24.31 gains and MYCN amplifi-
cations were present in different subsets of
neuroblastomas. Only 1 out of 14 (7%) 12q24.31-gained
neuroblastomas showed concomitant MYCN amplifica-
tion, which was detected in altogether 7 neuroblastoma
cases. Either MYCN amplification or 12q24.31 gain was
present in 64% of all neuroblastomas. Since 12q24.31 gain
did not associate with any of the other prognostic param-
eters, such as histology (INPC), stage, age and prolifera-
tion index (results not shown), our data suggest that it
may have independent prognostic value in neuroblas-
toma risk stratification. A Cox multivariate regression
analysis showed that age, stage and INPC did not con-
found the results.
Figure 3 Impact of copy number on gene expression in NGP and IMR-32 cells. Frequency of genes (Y-axis) whose expression was high (black 
bars) or low (gray bars) according to copy number ratios (X-axis). High-level expression was defined as the top 7th percentile of all expression ratios, 
while low-level expression was defined as the bottom 7th percentile. The number of genes in the different copy number classes is indicated in paren-
thesis.
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healthy nervous system samples
The expression levels of the control genes (MYCN,
MEIS1 and ALK) were, in all three cases, when compared
to all healthy samples, healthy nervous system samples
and healthy peripheral nervous system samples, highly
and statistically significantly elevated in neuroblastoma
(Table 2, Figure 5). Of the 40 genes in the 12q24.31 ampl-
icon, 25 (62.5%) had data in GeneSapiens. Among these
25 informative genes, five genes had statistically elevated
expression in neuroblastoma when compared to healthy
tissue samples, healthy nervous system and healthy
peripheral nervous system samples. These genes were
DIABLO (diablo homolog, Drosophila), ZCCHC8 (zinc
finger, CCHC domain containing 8), RSRC2 (arginine/
serine-rich coiled-coil 2), KNTC1 (kinetochore associ-
ated 1) and MPHOSPH9 (M-phase phosphoprotein 9)
(Table 2). Among these, DIABLO showed the strongest
and most specific activation in a subset of neuroblastoma
samples (Figure 6, see Additional files 1, 2, 3, and 4).
Discussion
Our integrative microarray-based analysis of gene copy
number and gene expression in two neuroblastoma cell
lines characterized many previously known genetic aber-
rations, and revealed a previously poorly characterized
amplification of 12q24.31 in neuroblastoma. The signifi-
cance of the detected 12q24.31 amplicon in clinical sam-
ples was further validated using the hotspot
neuroblastoma TMA format, which revealed low-level
gain of 12q24.31 in 42% of neuroblastoma patients.
Patients with 12q24.31 gain had an intermediate progno-
sis in comparison to patients with MYCN amplification
(poor prognosis) and patients having neither of the two
alterations (best prognosis) (P = 0.001). Moreover,
although the NGP cell line was shown to contain both
MYCN and 12q24.31 amplifications, we found only one
neuroblastoma in the tissue array analysis with both
genetic modifications. Whether the effects of the
12q24.31 gain and MYCN amplification represent actu-
ally two alternative routes in neuroblastoma progression,
remains, however, to be investigated further in separate
studies.
As neuroblastomas display vast intratumoral heteroge-
neity of various biological variables, including MYCN
copy number differences between cells [24], an overall
estimation of the prognostic impact of copy number
changes and other genetic alterations in one randomly
selected area of the tumor may be erroneous. Especially
low-level copy number increases of prognostically signifi-
cant genes or genomic regions are difficult to detect.
Moreover, since cancer cell lines often originate from a
single clone, the results of in vitro studies with cancer
cells lines are not necessarily applicable to intratumorally
heterogeneous tumors, such as neuroblastoma. There-
fore, on the basis that accelerated cell proliferation is
associated with progression-related chromosomal
changes, we measured the copy number of the 12q24.31
region in the most proliferative regions of neuroblastoma
samples, i.e. hotspots [20]. With this sensitive methodol-
ogy, low-level gain of 12q24.31 was shown to occur fre-
quently and define a biologically distinct subpopulation
of patients with intermediate outcome.
Supportive evidence of the 12q24 gain in neuroblas-
toma has recently been reported by Mosse and co-
authors [25]. In their BAC-array-based CGH study the
authors report 32% of the analyzed 82 primary tumors to
show low-level gain of 12q24 with minimal common
region between 110.8-132.4 Mb from the p-telomere. The
reported frequency resembles closely to that detected in
our hotspot FISH analysis (42%). Moreover, Mosse and
co-authors identified the low-level gain of 12q24 to corre-
late with aggressive clinical phenotype in a subset of
tumors without MYCN amplification. These data are in
excellent concordance with the data presented here.
In order to define activated genes within the detected
subtle copy number increase, we performed an in silico
analysis of vast amount of existing gene expression data
[22], including a considerable collection of normal
peripheral nervous system and neuroblastoma samples.
Using this approach we identified elevated expression of
five genes located at the 12q24.31 amplicon; DIABLO,
Figure 4 Kaplan-Meier analysis of the survival of patients with or 
without MYCN amplification and 12q24 gain. The prognosis of pa-
tients with 12q24 gain was intermediate when compared to those 
with MYCN amplification or patients with no amplification/gain of ei-
ther locus. Numbers in parenthesis refer to the number of patients in-
cluded in each category. Crosses indicate the lengths of follow-up for 
those patients whose follow-up was terminated before the last time 
point.
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Page 9 of 13ZCCHC8, RSRC2, KNTC1 and MPHOSPH9. Among
these five genes, DIABLO showed substantially elevated
expression levels in a subset of the neuroblastoma sam-
ples, suggesting that it may have an oncogenic role in
these tumors. DIABLO has been reported to have
proapoptotic effects in cells and therefore overexpression
of DIABLO is believed to cause antitumoral activity via
cancer cell sensitization to apoptotic cell death [26,27].
Even though the exact role of DIABLO in neuroblastoma
remains to be elucidated, previous contradictory results
suggest that DIABLO has both a direct and inverse corre-
lation to prognosis in various cancers. In cervical and
gastric cancer, DIABLO activation has been shown to
associate with unfavourable prognostic parameters [28-
30]. On the contrary, in renal cell carcinoma, lung cancer
and hepatocellular carcinoma, DIABLO expression asso-
ciates with favourable prognostic factors [31-33]. In this
sense, the carcinogenetic role of DIABLO is ambiguous,
and needs to be examined more thoroughly, also in neu-
roblastoma.
In addition to DIABLO, also ZCCHC8, RSRC2, KNTC1
and MPHOSPH9 showed statistically increased expres-
sion in neuroblastoma samples when compared to the
groups of healthy samples. Although the increase in
expression levels of these genes were marginal, which
could be argued to be due to impact of the detected low-
level gain, and the activation was not neuroblastoma spe-
cific, these genes may also have a role in neuroblastoma.
Moreover, as only 63% of the genes within the detected
amplicon were informative in the in silico analysis, we
cannot rule out the possibility that additional oncogenic
genes may reside at 12q24.31.
Data integration at the DNA and RNA level provided
evidence that several previously known oncogenes were
activated due to DNA amplification at corresponding
sites. These previously known oncogenes included
MYCN (in the IMR-32 and NGP cell lines), as well as
ALK, MEIS1 and TEM8 (in the IMR-32 cell line) [34-37],
which all located at 2p. In addition to oncogene activa-
tions at 2p, distinct high-level amplification sites were
mapped at high-resolution along chromosome 12 (at q14,
q15, q24.11 and q24.31) in the NGP cell line. In addition
to the genes previously implicated in the 12q14 and q15
amplicons, such as SAS and MDM2, we found amplifica-
tion and overexpression of several other genes, including
CENTG1 and AVIL at 12q14, and FRS2, CPM and CPSF6
at 12q15. In addition to DIABLO, our data revealed sev-
eral unreported, amplified and overexpressed genes in
the 12q24.31 region, locus from which only restin
(CLIP1/RSN) has been previously shown to be amplified
in NGP cells [38]. Within the limits of this study, the
detected gene amplifications may serve as additional data
in future research on prognostically significant genetic
alterations in neuroblastoma.
Recently, few large studies with high-resolution
genome-wide copy number analysis have been published
[25,39,40]. Some of these studies include, similarly to this
study, parallel gene expression analysis allowing the iden-
tification of concomitant alterations in copy number and
expression level [25,39]. The obvious strength of these
studies is the vast number of samples included in the
analyses. Although the study presented here is limited by
the sample size in the initial aberration discovery phase,
we show that the utilization of only a few representative
Table 2: Analysis of in silico gene expression data with Mann-Whitney-Wilcoxon rank sum method (MWW) revealed 
elevated expression of five genes at 12q24.31 amplicon.
Gene name/Genomic 
location
P-value for test that expression is higher in neuroblastoma than in
healthy nervous system 
samples
healthy peripheral nervous 
system samples
all healthy tissue samples
MYCN/2p24.1 <1e-16 6.2e-11 <1e-16
ALK/2p23 <1e-16 3.6e-7 <1e-16
MEIS1/2p14-p13 <1e-16 9.64e-13 <1e-16
DIABLO/12q24.31 <1e-16 0.00302 <1e-16
ZCCHC8/12q24.31 <1e-16 <1e-16 1e-05
RSRC2/12q24.31 <1e-16 0.00031 <1e-16
KNTC1/12q24.31 <1e-16 <1e-16 <1e-16
MPHOSPH9/12q24.31 <1e-16 <1e-16 <1e-16
Gene expression levels between 22-123 neuroblastoma samples and healthy tissue samples, including 308-445 healthy nervous system 
(including central and peripheral nervous system samples) and 18-20 peripheral nervous system samples, were examined. In addition to the 
12q24.31 amplicon genes, MYCN, ALK and MEIS1 were included in the analysis as controls. The analysis showed statistically elevated 
expression of DIABLO, ZCCHC8, RSRC2, KNTC1 and MPHOSPH9 in neuroblastoma samples (P < 0.01).
Wolf et al. BMC Cancer 2010, 10:181
http://www.biomedcentral.com/1471-2407/10/181
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Figure 5 In silico gene expression profiles for MYCN, ALK and MEIS1. Box plot analysis of the MYCN, ALK and MEIS1 expression levels across several 
normal (green boxes) and cancer tissues (red boxes). The number of samples included in each tissue type is indicated in parenthesis. Normal central 
nervous system and peripheral nervous system samples, as well as neuroblastoma samples are highlighted with green and red rectangles, respective-
ly. The expression levels of all three control genes are highly elevated in neuroblastoma.
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Figure 6 In silico gene expression data suggest a role for DIABLO in neuroblastoma. Box plot analysis of the DIABLO expression levels across nor-
mal (green boxes) and cancer tissues (red boxes). The number of samples included in each tissue type is indicated in parenthesis. Normal central ner-
vous system and peripheral nervous system samples, as well as neuroblastoma samples are highlighted with green and red rectangles, respectively. 
DIABLO shows a clear activation in a subset of neuroblastoma samples.
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Page 11 of 13model systems can, nevertheless, be used to identify clin-
ically relevant data. Furthermore, the in silico data mining
approach used here for evaluating transcriptional conse-
quences of the detected aberration shows the power of
utilization of previously published gene expression data
providing a rapid and cost-effective tool for the discovery
of new biomarkers.
Conclusions
Our results illustrate that the integration of array-based
profiling at DNA, RNA and tissue levels is a powerful
strategy in the identification of amplified genes with
simultaneous overexpression, and highlights the signifi-
cance of in silico data mining opportunities in providing
further evidence of putative activated genes involved in
cancer progression. In addition to confirming previously
identified oncogenes in neuroblastoma, our analysis led
to the identification of 12q24.31 gain as a novel marker in
neuroblastoma progression, as well as upregulation of
DIABLO specifically in a subset of neuroblastoma sam-
ples within this region. Clearly, extensive functional and
clinical investigations are needed to understand the com-
plete role of this apoptosis-related protein in neuroblas-
toma pathobiology before its potential as a therapeutic
target or predictor of outcome can be determined.
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